Sapient Capital LLC Trims Position in Liquidia Corporation $LQDA

Sapient Capital LLC reduced its position in shares of Liquidia Corporation (NASDAQ:LQDA) by 37.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,000 shares of the company’s stock after selling 14,000 shares during the quarter. Sapient Capital LLC’s holdings in Liquidia were worth $1,834,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after acquiring an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares during the period. Creative Planning raised its holdings in Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the period. Finally, Legal & General Group Plc lifted its position in Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after purchasing an additional 11,111 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of Liquidia stock opened at $68.66 on Friday. The stock has a 50 day moving average of $78.51 and a 200 day moving average of $58.11. Liquidia Corporation has a 12 month low of $21.15 and a 12 month high of $93.61. The firm has a market cap of $6.15 billion, a PE ratio of 50.12 and a beta of 0.53. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. During the same period last year, the business posted ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. On average, research analysts expect that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The FDA granted Fast Track designation to YUTREPIA (treprostinil inhalation powder) for systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP). The designation provides more frequent FDA interactions and potentially enables rolling review, Priority Review or Accelerated Approval if applicable. FDA Grants Fast Track Designation to YUTREPIA
• Positive Sentiment: Liquidia plans to begin the approximately 75-patient RE-WARM Phase 2a dose-finding study in October 2026, targeting primary completion in February 2027. SSc-RP affects a substantial population, has no FDA-approved U.S. therapy and represents a potential expansion opportunity for YUTREPIA. Liquidia Gains FDA Fast Track for YUTREPIA
• Positive Sentiment: Coverage highlighted that the YUTREPIA launch is continuing to outperform expectations, supporting the investment case for Liquidia’s commercial execution and revenue growth. YUTREPIA Launch Continues to Outpace Expectations
• Neutral Sentiment: Analysts collectively maintain an average “Hold” rating, indicating that the positive regulatory and commercial developments are balanced by valuation, execution and clinical-development uncertainty. Liquidia Receives Average Hold Rating
• Negative Sentiment: Fast Track is not approval: YUTREPIA’s safety and efficacy for SSc-RP have not been established, and the company must still produce favorable Phase 2a and later-stage data. The indication therefore carries meaningful clinical and regulatory risk. Liquidia Receives FDA Fast Track Designation

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LQDA shares. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Bank of America lifted their price target on shares of Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Needham & Company LLC upped their price target on shares of Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Stephens set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $98.08.

Insider Activity at Liquidia

In related news, insider Jason Adair sold 73,631 shares of Liquidia stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the completion of the sale, the insider owned 174,606 shares in the company, valued at $12,063,528.54. This trade represents a 29.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen M. Bloch sold 242,269 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares of the company’s stock, valued at approximately $82,838,639.12. This trade represents a 17.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,539,210 shares of company stock valued at $111,412,994 in the last 90 days. Company insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).